Compare RGR & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGR | ARVN |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.9M | 600.2M |
| IPO Year | 1994 | 2018 |
| Metric | RGR | ARVN |
|---|---|---|
| Price | $43.56 | $7.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 16 |
| Target Price | ★ $43.00 | $13.93 |
| AVG Volume (30 Days) | 216.8K | ★ 797.9K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | 0.44 | ★ 1.70 |
| Revenue | ★ $546,057,000.00 | $262,600,000.00 |
| Revenue This Year | $6.89 | $12.76 |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | $99.11 | ★ $4.42 |
| Revenue Growth | ★ 1.94 | N/A |
| 52 Week Low | $28.33 | $6.97 |
| 52 Week High | $48.21 | $14.22 |
| Indicator | RGR | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 66.12 | 42.54 |
| Support Level | $36.79 | N/A |
| Resistance Level | $44.00 | $8.52 |
| Average True Range (ATR) | 0.87 | 0.32 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 66.75 | 33.10 |
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.